Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
US Department of Justice
Boehringer Ingelheim
Citi
Deloitte
Johnson and Johnson
UBS
Daiichi Sankyo

Generated: June 23, 2018

DrugPatentWatch Database Preview

Tentative Approvals for: Ranbaxy Labs Ltd

« Back to Dashboard

Ranbaxy Labs Ltd Drugs with Tentative Approvals

Applicant Generic Name NDA Strength Dosage Form
Ranbaxy Labs Ltd glimepiride 076875 8MG TABLET;ORAL
Ranbaxy Labs Ltd glimepiride 076875 1MG TABLET;ORAL
Ranbaxy Labs Ltd cetirizine hydrochloride 077472 5MG/5ML SYRUP;ORAL
Ranbaxy Labs Ltd fluconazole 076386 50MG TABLET;ORAL
Applicant Generic Name NDA Strength Dosage Form

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
McKinsey
Healthtrust
Harvard Business School
Boehringer Ingelheim
Express Scripts
Federal Trade Commission
Deloitte
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.